Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > McWhirter Link

<< Previous

Bullboard Posts

Next >>

Comment by PhillUpBankson Jun 30, 2020 6:14pm

294 Views

Post# 31210323

RE:RE:RE:RE:RE:McWhirter Link

Ralph I do not believe the latest Deal for 28 million(or whatever the exact amount) was intended for phase 3. The company has stated this a few times. I believe they have another direction in mind or they could have raised enough to go through phase 3 alone.. but i am just making assumptions like everyone else. None of us "stock house experts" really know I guess we just have to make our own educated knowledge with the information and data we are given.

<< Previous

Bullboard Posts

Next >>

BlackBerry’s cost-cutting yields Q1 2024 savings